Desvenlafaxine

SNRI·Psychiatry - Antidepressants

Major Depressive Disorder (MDD)

PBSSNRIPristiq50 mg tabletS4+1

Max Dose

200 mg/day

Half-life

11 h

CYP Metabolism

MINIMAL

Hypertension

RISK

Rapid Summary

Overview

The active major metabolite of Venlafaxine. Bypasses the need for liver CYP2D6 activation. Provides highly predictable blood levels and avoids the drug interactions of standard Venlafaxine.

Maximum Dose

Max 200 mg/day (though doses > 50 mg rarely provide extra psychiatric benefit, just more side effects).

Clinical Focus

Cleared almost entirely by the kidneys. Avoid in severe renal failure.

Bottom Line

Desvenlafaxine is the active metabolite of venlafaxine with simpler dosing and fewer drug interactions, but offers no clear efficacy advantage and shares the same discontinuation syndrome.

Formulation & Access

Brand Names

Pristiq

Oral Routes

Do not crush

Extended Release (ER) Tablets (50 mg, 100 mg). Do NOT crush. Empty ghost tablet will pass in stool.

Prescribing & PBS

Unrestricted General Benefit (S4).

Indications & Use

Primary

PBSTGA

Major Depressive Disorder (MDD).

Off-Label

OFF

Vasomotor symptoms (hot flushes) in menopause.

Clinical Place

Preferred over Venlafaxine for patients taking multiple medications (due to zero CYP interactions) or known CYP2D6 poor metabolizers.

Quick reference

Class & Role

SNRI — The active major metabolite of Venlafaxine.

Route / Formulation

Extended Release (ER) Tablets (50 mg, 100 mg). Do NOT crush. Empty ghost tablet will pass in stool. (Pristiq)

Usual Dose & Max

PO 50 mg OD. May increase to 100 mg/day if needed, but 50 mg is the standard therapeutic dose. Max 200 mg/day (though doses > 50 mg rarely provide extra psychiatric benefit, just more side effects).

Key Indication Doses

Major Depressive Disorder: PO 50 mg OD. May increase to 100 mg/day if needed, but 50 mg is the standard therapeutic dose. Renal Impairment: If eGFR 30-50, Max 50 mg/day. If eGFR < 30, give 50 mg EVERY OTHER DAY.

Best Uses

Desvenlafaxine is the active metabolite of venlafaxine with simpler dosing and fewer drug interactions, but offers no clear efficacy advantage and shares the same discontinuation syndrome.

Avoid / Cautions

Concurrent MAOI use. Pregnancy Category B2.

Key Risks

Gastrointestinal: Nausea, dry mouth, constipation. Neurological: Insomnia, dizziness, hyperhidrosis (severe sweating). Discontinuation syndrome (brain zaps). Cardiovascular: Hypertension, tachycardia.

Key Interactions

MAOIs, Tramadol, St John's Wort (Serotonin Syndrome). Unlike Venlafaxine, it has zero significant CYP450 interactions, making it highly safe to mix with Tamoxifen, Statins, or heart meds.

Monitoring

Monitor BP prior to starting and regularly during therapy. Check eGFR (Requires good kidney function to clear).

Clinical Pearl

In clinical trials, 50 mg of Desvenlafaxine worked just as well as 100 mg or 200 mg for depression, but higher doses had double the side effects. Resist the urge to up-titrate rapidly if 50 mg fails; switch drugs instead.

Access

Pristiq50 mg tablet

Brand: Pristiq
Formulation: Extended Release (ER) Tablets (50 mg, 100 mg)

Desvenlafaxine

SNRI·Psychiatry - Antidepressants

Major Depressive Disorder (MDD)

PBSSNRIPristiq50 mg tabletS4+1

Max Dose

200 mg/day

Half-life

11 h

CYP Metabolism

MINIMAL

Hypertension

RISK

Rapid Summary

Overview

The active major metabolite of Venlafaxine. Bypasses the need for liver CYP2D6 activation. Provides highly predictable blood levels and avoids the drug interactions of standard Venlafaxine.

Maximum Dose

Max 200 mg/day (though doses > 50 mg rarely provide extra psychiatric benefit, just more side effects).

Clinical Focus

Cleared almost entirely by the kidneys. Avoid in severe renal failure.

Bottom Line

Desvenlafaxine is the active metabolite of venlafaxine with simpler dosing and fewer drug interactions, but offers no clear efficacy advantage and shares the same discontinuation syndrome.

Formulation & Access

Brand Names

Pristiq

Oral Routes

Do not crush

Extended Release (ER) Tablets (50 mg, 100 mg). Do NOT crush. Empty ghost tablet will pass in stool.

Prescribing & PBS

Unrestricted General Benefit (S4).

Indications & Use

Primary

PBSTGA

Major Depressive Disorder (MDD).

Off-Label

OFF

Vasomotor symptoms (hot flushes) in menopause.

Clinical Place

Preferred over Venlafaxine for patients taking multiple medications (due to zero CYP interactions) or known CYP2D6 poor metabolizers.

Quick reference

Class & Role

SNRI — The active major metabolite of Venlafaxine.

Route / Formulation

Extended Release (ER) Tablets (50 mg, 100 mg). Do NOT crush. Empty ghost tablet will pass in stool. (Pristiq)

Usual Dose & Max

PO 50 mg OD. May increase to 100 mg/day if needed, but 50 mg is the standard therapeutic dose. Max 200 mg/day (though doses > 50 mg rarely provide extra psychiatric benefit, just more side effects).

Key Indication Doses

Best Uses

Desvenlafaxine is the active metabolite of venlafaxine with simpler dosing and fewer drug interactions, but offers no clear efficacy advantage and shares the same discontinuation syndrome.

Avoid / Cautions

Concurrent MAOI use. Pregnancy Category B2.

Key Risks

Key Interactions

MAOIs, Tramadol, St John's Wort (Serotonin Syndrome). Unlike Venlafaxine, it has zero significant CYP450 interactions, making it highly safe to mix with Tamoxifen, Statins, or heart meds.

Monitoring

Monitor BP prior to starting and regularly during therapy. Check eGFR (Requires good kidney function to clear).

Clinical Pearl

Access

Pristiq50 mg tablet

Brand: Pristiq
Formulation: Extended Release (ER) Tablets (50 mg, 100 mg)